iStent inject W with Infinite Injector Technology
Mild to moderate primary open-angle glaucoma with cataract surgery
ApprovedCommercial
Key Facts
Indication
Mild to moderate primary open-angle glaucoma with cataract surgery
Phase
Approved
Status
Commercial
Company
About Glaukos
Glaukos Corporation (NASDAQ: GKOS) is transforming the treatment of chronic eye diseases through innovative medical devices and pharmaceutical solutions. The company has built a comprehensive portfolio spanning three key ophthalmic areas: glaucoma (featuring the market-leading iStent family), corneal health (including the iLink cross-linking system for keratoconus), and retinal disease drug delivery platforms. With over 300 peer-reviewed publications supporting their MIGS technology and reinvesting approximately 30% of sales into R&D, Glaukos continues to pioneer novel therapies that advance standards of care for millions of patients worldwide.
View full company profile